Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD (XCGD-MOBI)
A Multicentric, Exploratory, Non-randomised, Non-controlled, Prospective, Open-label Phase II Study Evaluating Safety and Efficacy of IBU, G-CSF and Plerixafor as Stem Cell Mobilization Regimen in Patients Affected by X-CGD
Sponsor: Fondazione Telethon
Listed as NCT03055247, this PHASE2 trial focuses on Chronic Granulomatous Disease X-linked (X-CGD) and remains actively recruiting participants. Sponsored by Fondazione Telethon, it has been updated 10 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Oct 2025 — Present [monthly]
Recruiting PHASE2
Status: Unknown → Recruiting
-
Nov 2024 — Oct 2025 [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
▶ Show 5 earlier versions
-
Jan 2021 — Nov 2022 [monthly]
Unknown Status PHASE2
-
Jun 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fondazione Telethon
- IRCCS San Raffaele
For direct contact, visit the study record on ClinicalTrials.gov .